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Rituximab Exerts a Dual Effect in Pemphigus Vulgaris
Ru¨diger Eming1,3, Angela Nagel1,3, Sonja Wolff-Franke1, Eva Podstawa1, Dirk Debus2 and Michael Hertl1
Pemphigus vulgaris (PV) is a severe autoimmune blistering disease affecting the skin and mucous membranes.
Autoreactive CD4þ T helper (Th) lymphocytes are crucial for the autoantibody response against the
desmosomal adhesion molecules, desmoglein (dsg)-3 and dsg1. Eleven patients with extensive PV were treated
with the anti-CD20 antibody, rituximab (375mg per m2 body surface area once weekly for 4 weeks). Frequencies
of autoreactive CD4þ Th cells in the peripheral blood of the PV patients were determined 0, 1, 3, 6, and 12
months after rituximab treatment. Additionally, the clinical response was evaluated and serum autoantibody
titers were quantified by ELISA. Rituximab induced peripheral B-cell depletion for 6–12 months, leading to a
dramatic decline of serum autoantibodies and significant clinical improvement in all PV patients. The
frequencies of dsg3-specific CD4þ Th1 and Th2 cells decreased significantly for 6 and 12 months, respectively,
while the overall count of CD3þCD4þ T lymphocytes and the frequency of tetanus toxoid-reactive CD4þ Th
cells remained unaffected. Our findings indicate that the response to rituximab in PV involves two mechanisms:
(1) the depletion of autoreactive B cells and (2) the herein demonstrated, presumably specific downregulation
of dsg3-specific CD4þ Th cells.
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INTRODUCTION
Pemphigus vulgaris (PV) is a severe, potentially life-threaten-
ing autoimmune disease, clinically characterized by
extensive blisters and erosions of the skin and mucous
membranes. It is associated with IgG autoantibodies (autoab),
which target desmoglein (dsg)-1 and dsg3, two transmem-
branous adhesion glycoproteins of desmosomes. There are
ample data demonstrating that anti-dsg-IgG autoab are
directly responsible for the loss of epidermal cell–cell
adhesion, which is a characteristic hallmark of PV (Payne
et al., 2004). Although pemphigus is considered as a
paradigm of an autoab-mediated organ-specific autoimmune
disease, its induction and perpetuation is thought to be
controlled by dsg1/dsg3-specific autoreactive CD4þ T cells
(Hertl et al., 2006). There is increasing evidence for the
successful application of the monoclonal anti-CD20 anti-
body, rituximab, in severe and refractory PV, due to its
B-cell-depleting effect (Arin et al., 2005; Schmidt et al.,
2006). Ahmed et al. (2006) and Joly et al. (2007) demon-
strated in two independent prospective trials that rituximab
in combination with high-dose intravenous immunoglobulins
or in combination with systemic glucocorticoids, causes
long-term clinical remissions in PV. Both studies explain
the observed dramatic clinical response by the depletion
of autoreactive B cells as progenitors of autoab-secreting
plasma cells.
In this study, we demonstrate that rituximab exerts an
additional effect on dsg3-specific, autoreactive CD4þ T
helper (Th) cells that are thought to be critical for the
regulation of the pathogenic autoab response in PV. Eleven
PV patients with severe and/or recalcitrant disease who
received one cycle of rituximab treatment combined with
systemic immunosuppression were included in this study.
Over a 12-month period on rituximab treatment, we assessed
the frequencies of dsg3-specific Th1 and Th2 cells in the
blood of the treated PV patients. Additional parameters
included IgG titers of pathogenic dsg1/dsg3-specific autoab,
lymphocyte subsets, and clinical scores. Our results demon-
strate a significant decrease of autoreactive dsg3-specific
CD4þ Th cells, which was directly linked to rituximab-
induced B-cell depletion—and more delayed—a significant
decrease of anti-dsg3-specific autoab. In contrast, the
frequency of tetanus toxoid (TT)-specific Th1 cells and the
titers of TT-reactive IgG remained largely unaffected by
rituximab treatment. Thus, our observations provide evidence
for a second, not yet described and presumably specific effect
of rituximab on dsg3-reactive Th cells, which may contribute
to the observed fast and long-term clinical responses in PV.
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RESULTS
Clinical response to rituximab treatment in severe PV
The clinical outcome of rituximab treatment was monitored
over a period of 12 months utilizing the recently introduced
disease score, ABSIS (Autoimmune Bullous Skin disease
Intensity Score) (Pfutze et al., 2007). Figure 1 illustrates the
clinical course of a representative 24-year-old female PV
patient with extensive cutaneous and mucosal erosions
unresponsive to previous high-dose immunosuppressive
medication. She experienced complete healing of the
cutaneous and mucosal lesions within 6 months after ritu-
ximab treatment accompanied by a fast and complete
reduction of the ABSIS score for cutaneous and mucosal
involvement and the absence of dsg1/dsg3-specific IgG
autoab. Between 6 and 12 months after rituximab treatment,
three PV patients experienced a clinical relapse, whereas
seven patients presented with ongoing complete clinical
remission. Nevertheless, the overall ABSIS scores for both
cutaneous and mucosal lesions demonstrated a significant
reduction for the complete follow-up period (Figure 2a and b).
Decline of dsg3-reactive autoab titers following rituximab
treatment
Figure 3 summarizes the effect of rituximab treatment on
dsg3-specific autoab titers. In all 11 PV patients, the titers of
dsg3-reactive IgG decreased continuously and significantly
to 30–40% of the pretreatment values within 12 months after
rituximab (Figure 3a). Eight PV patients who remained in
complete clinical remission demonstrated decreased autoab
titers (Figure 3b), whereas the levels of dsg3-specific IgG in
three relapsing patients increase between 6 and 12 months
again (Figure 3c). Moreover, the pathogenetically relevant,
dsg3-reactive IgG1 (Figure 3, centre column) and IgG4 autoab
isotypes (Figure 3, right column) showed a similar decline
after rituximab. Noteworthy, the titers of anti-dsg3-IgG4
autoab significantly dropped within 1 month (P¼0.007)
accompanied by an early onset of the clinical response,
whereas the decline of total anti-dsg3-IgG titers was not
statistically significant at this early time point (P40.05).
Rituximab does not alter the overall numbers of peripheral
T lymphocytes
To evaluate the effect of rituximab treatment on the peri-
pheral CD4þ and CD8þ T-cell compartments, in general,
lymphocyte subset analyses of peripheral blood mononuclear
cells (PBMCs) were performed at various time points during
the follow-up period. Figure 4a shows that rituximab
treatment had an effect neither on total T-cell numbers
nor on the CD3þCD4þ and CD3þCD8þ T cell subsets.
Moreover, the clinical course of the disease did not alter the
number of CD3þ T cell subsets. Specifically, patient PV2
(Figure 4b) representing the group of patients in clinical
remission at 12 months after rituximab and patient PV10
(Figure 4b) who represents the group of patients with
a clinical relapse showed stable CD3þ T cell counts. Thus,
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Figure 1. Clinical response to rituximab in recalcitrant pemphigus vulgaris
(PV). Clinical course of a representative patient with chronic erosions of
the face and scalp (partly shown) before rituximab treatment and 3 and
12 months afterward, respectively. Complete clinical remission as illustrated
by reduction of the disease scores for cutaneous (ABSIS cut) and mucosal
(ABSIS mc) involvement was paralleled by a decrease of desmoglein1 (dsg1)-
and dsg3-reactive IgG autoantibodies.
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Figure 2. Rituximab induces prolonged clinical remission of cutaneous and
mucosal erosions in severe pemphigus vulgaris (PV). The profound clinical
response to rituximab treatment is shown as strongly reduced ABSIS scores
for (a) cutaneous and (b) mucosal lesions. Score values are illustrated as
median±range and the numbers of PV patients studied at the different time
points are shown in parenthesis. Statistical significance is demonstrated as
P-values at the respective time points (*Po0.05).
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B-cell depletion caused by rituximab does not exert global
inhibitory effects on the different T-cell subsets.
Rituximab induces a prolonged B-cell depletion and a
significant decrease of dsg3-specific CD4þ T cells
Figure 5 summarizes the frequencies of peripheral dsg3-
reactive CD4þ T cells and the percentages of CD19þ
peripheral B cells in the studied PV patients after rituximab
treatment. Within 1–3 months, rituximab induced a dramatic
decrease of dsg3-reactive Th1 and Th2 cells, respectively, in
all 11 PV patients (Figure 5a). The number of dsg3-reactive,
IFNg-secreting Th1 cells decreased from 18 cells per 105
PBMC to 12 cells per 105 PBMCs 1 month after rituximab
treatment. The decrease of IL4þ Th2 cells from 20 cells per
105 PBMC to 7 cells per 105 PBMC at this time point was
even more pronounced, and the frequency of autoreactive
Th2 cells remained at 30% of the pretreatment values
throughout the complete follow-up period of 12 months
(Figure 5a). The rituximab-induced decline of dsg3-reactive
Th2 and Th1 subsets was statistically significant for the period
of 12 months (for Th2) and up to 6 months (for Th1),
respectively (*Po0.05, **Po0.01). Figure 5b and c illustrate
the frequencies of dsg3-reactive Th1 and Th2 cells for the
subgroups of treated PV patients with ongoing clinical
remission (Figure 5b) and those patients who experienced a
clinical relapse between 6 and 12 months after rituximab
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Figure 3. Rituximab leads to a decrease of desmoglein 3 (dsg3)-reactive autoantibodies. The relative decrease of dsg3-specific IgG autoantibodies as shown
for total IgG (left column), IgG1 (centre column), and IgG4-subtypes (right column), respectively, is illustrated. Panel (a) summarizes the autoantibody levels
of all 11 PV patients, whereas the 8 patients who were in clinical remission are shown in panel (b). (c) Dsg3-reactive autoantibody titers of three PV patients
who experienced a clinical relapse between 6 and 12 months after rituximab demonstrate increasing autoantibody titers again at 12 months after therapy.
Pretreatment autoantibody values are set as 100%. Statistical significance is indicated as P-values for the respective time points during follow-up
(*Po0.05, **Po0.01). The numbers of PV patients investigated at the different time points are shown in parentheses.
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treatment (Figure 5c). Despite comparable B-cell frequencies
at different time points after rituximab treatment in the two
subgroups, the frequencies of both dsg3-specific Th1 and Th2
cells remained low in patients with ongoing clinical
remission as shown in Figure 5b (median for IFNg-positive
Th1 cells was 7 per 105 PBMC for 6 and 12 months,
respectively, and 8 cells per 105 PBMC at 6 months and 7
cells per 105 PBMC at 12 months for IL4þ Th2 cells), whereas
in three relapsing PV patients, the frequencies of both dsg3-
specific Th1 and Th2 cells reincreased between 6 and 12
months after rituximab treatment. Figure 5c demonstrates that
median frequencies of autoreactive Th1 and Th2 cells
increased from 7 cells per 105 PBMC at 6 months to 13 cells
per 105 PBMC again at 12 months after B-cell depletion in
this group of patients. Statistical analysis could not be
performed at this point, due to the small number of three
relapsing PV patients. Thus, the frequencies of dsg3-reactive
Th cells were directly linked to the observed clinical status of
the PV patients. Interestingly, looking at individual patients,
the decrease of dsg3-reactive CD4þ T cells preceded the
decline in dsg3-specific autoab titers as shown for one
representative PV patient (PV1) (Figure S1). Whereas the
frequencies of dsg3-reactive Th1 and Th2 cells decreased
from 32 cells per 105 PBMC before rituximab treatment to
8 cells per 105 PBMC 3 months after rituximab, the titers of
dsg3-specific IgG declined between 3 and 6 months after
anti-CD20 Ab treatment. The direct correlation of dsg3-
reactive T-cell frequencies and the titers of dsg3-specific IgG
is illustrated by investigating the three relapsing PV patients
(Figure S2). Both the frequencies of dsg3-reactive Th1 and
Th2 cells paralleled the initial decline in dsg3-specific autoab
within the first 6 months after rituximab treatment and
demonstrated a reincrease between 6 and 12 months at the
time of the clinical relapse (Figure S2). Noteworthy, treatment
with immunosuppressives and adjuvant immunoadsorption,
respectively, did not affect the frequency of dsg3-reactive
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Figure 4. Effect of rituximab on peripheral T-cell subsets. Percentages of total CD3þ T cells, CD3þCD4þ , and CD3þCD8þ T cell subsets, respectively, in
all 11 pemphigus vulgaris (PV) patients upon treatment with rituximab (a) are shown. Panel (b) summarizes the frequencies of dsg3-reactive Th1 and Th2 cells
in a representative PV patient (PV2) who was in ongoing clinical remission at 12 months after rituximab and in a second PV patient (PV10) experiencing
a clinical relapse between 6 and 12 months after rituximab. Irrespective of the clinical course of the disease, total CD3þ T cell counts as well as CD4þ
and CD8þ T-cell subpopulations remained unaffected by rituximab therapy.
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CD4þ T cells. One PV patient receiving high-dose corticos-
teroids combined with mycophenolate mofetil showed stable
frequencies of dsg3-reactive, IL4þ T cells at the beginning of
the treatment (16 IL4þ Th2 cells per 105 PBMC) and 5
months later (13 per 105 IL4þ Th2 cells). At this time, the
patient was treated with adjuvant immunoadsorption and
directly after immunoadsorption, the frequency remained at
13 per 105 dsg3-reactive IL4þ Th2 cells (data not shown),
suggesting that the decline in dsg3-reactive CD4þ T cells
observed in this study is restricted to rituximab treatment.
TT-specific CD4þ T-cell responses are unaffected by anti-CD20
Ab treatment
To analyze the effect of rituximab-induced B-cell depletion
on T cells of unrelated specificity such as pathogen-specific
memory CD4þ T cells, we also studied the frequency of
IFNg-positive Th1 cells reactive to the recall antigen TT by
magnetic activated cell sorting (MACS)-secretion assay.
Figure 6a and b demonstrate the frequencies of IFNg-positive,
TT-reactive Th1 cells and titers of TT-reactive IgG in two
studied PV patients. In both patients, the frequencies of
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Figure 5. Prolonged suppression of desmoglein 3 (dsg3)-reactive CD4þ T cells by rituximab. Panel (a) illustrates the frequencies of dsg3-reactive Th1 (IFNgþ )
(left figure) and Th2 (IL4þ ) (center figure) CD4þ T cells per 105 PBMC in all 11 PV patients. Additionally, the percentages of CD19þ B cells in peripheral blood
are provided (right figure). The decrease of dsg3-specific Th1 cells is statistically significant for up to 6 months after therapy (*Po0.05, **Po0.01), whereas the
decrease of dsg3-specific Th2 cell numbers and of B cells is statistically significant for the entire follow-up period of 12 months (*Po0.05, **Po0.01). Panel (b)
shows the frequencies of dsg3-specific Th1 and Th2 cells and of CD19þ B cells, respectively, in the group of 8 PV patients who were in complete clinical
remission 12 months after rituximab treatment. In contrast, three PV patients experienced a relapse of disease activity 12 months after rituximab, whose
frequencies of both dsg3-reactive Th1- and Th2-cells increased again at this time point, as shown in panel (c). Statistical significance is demonstrated as P-values
at the respective time points (*Po0.05, **Po0.01).
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TT-reactive Th1 cells remained unchanged (40 and 20 IFNgþ
T cells per 105 PBMC, respectively) during the entire 12-
month follow-up after rituximab. On the opposite, upon
treatment with rituximab, the frequencies of dsg3-specific
Th1 and Th2 cells from the same PV patients dropped
significantly to 45 and 30% of the pretreatment values,
respectively (data not shown). These results strongly suggest a
differential effect of rituximab-induced B-cell depletion on
autoreactive versus pathogen-specific CD4þ T cells. The
titers of TT-reactive IgG increased in both patients within the
12 months follow-up period.
DISCUSSION
These findings strongly suggest that rituximab exhibits a dual
effect in PV patients by (1) depleting CD20þ autoreactive B
cells as progenitors of autoab-secreting plasma cells and (2)
indirectly decreasing the frequency of autoreactive CD4þ T
cells via depletion of B cells as presumably critical antigen-
presenting cells. It is likely that similar mechanisms of action
contribute to the encouraging results obtained with rituximab
in other autoimmune diseases, such as rheumatoid arthritis,
lupus erythematosus, dermatomyositis, and various forms of
vasculitides (Arin et al., 2005).
Our results are in line with previous reports demonstrating
a sustained reduction of circulating anti-dsg1/anti-dsg3 IgG
levels by rituximab correlating well with an excellent clinical
response (Ahmed et al., 2006; Joly et al., 2007). An
additional, not yet described, important observation is the
immediate and prolonged reduction of dsg3-reactive Th cells
by rituximab treatment. Our group and others identified and
functionally characterized autoreactive CD4þ T cells in the
peripheral blood of PV patients, which target distinct epitopes
of dsg3 (Wucherpfennig et al., 1995; Lin et al., 1997; Hertl
et al., 1998; Veldman et al., 2003, 2004). Several in vivo and
in vitro studies strongly support the concept that dsg3-
reactive CD4þ T cells are critical for the initiation and
perpetuation of the autoab response in PV patients, as Th
cells provide crucial help for the activation of autoreactive
memory B cells (Nishifuji et al., 2000; Tsunod et al., 2002;
Eming et al., unpublished data). Yet unappreciated is the
function of autoreactive B cells as antigen-presenting cells for
dsg3-specific CD4þ Th cells in PV. The uptake of autoanti-
gens through surface immunoglobulins by B cells with
subsequent processing and presentation to autoreactive
CD4þ T cells is well known (Dai et al., 2005). The
importance of the reciprocal T–B cell interaction in systemic
autoimmune diseases such as lupus erythematosus has
recently been emphasized (Shlomchik et al., 2001). Further-
more, B cells have been shown to provide highly efficient
antigen presentation, which is essential for the optimal
expansion of activated T cells and the generation of memory
T cells in mice (Kleindienst and Brocker, 2005; Crawford
et al., 2006). In all the 11 PV patients of this study, rituximab
induced a significant decrease of autoreactive T-cell subsets
implicated in the regulation of B-cell activation, that is, dsg3-
specific CD4þ Th2 cells, which lasted up to 12 months.
Interestingly, three PV patients experienced a clinical relapse
occurring between 6 and 12 months after rituximab
treatment, which was accompanied by an increase of dsg3-
specific Th cell frequencies (Figure 5c), whereas the number
of both autoreactive Th1 and Th2 cells in the remaining eight
PV patients in complete clinical remission remained dimin-
ished (Figure 5b). Thus, we observed a close correlation of
dsg3-specific Th cell frequencies and the titers of dsg3-
specific autoabs, both related to the clinical course of PV.
Noteworthy, a recently described subset of IL-10-producing,
dsg3-specific T cells with regulatory function (Veldman et al.,
2004) was not significantly reduced, suggesting that ritux-
imab treatment did not affect peripheral tolerance to dsg3
mediated by this particular T cell subset (data not shown).
With regard to naturally occurring CD4þCD25þ regulatory
T cells (Treg), two recent reports suggest that in patients with
systemic lupus erythematosus and lupus nephritis, respec-
tively, the frequencies of Treg increase after rituximab
treatment (Vallerskog et al., 2006; Sfikakis et al., 2007).
Possibly, this induction of Treg might contribute to the
decrease of autoreactive CD4þ T cell clones and finally to
the clinical reponse of the PV patients. However, our
experimental setting does not rule out that due to ritux-
imab-induced B-cell depletion, dsg3-reactive CD4þ T cells
remained unresponsive to in vitro stimulation with dsg3 and
were thus not detected by MACS assay. This would strongly
support the role of autoreactive B cells as antigen-presenting
cells in vitro.
A major finding of this study was the observed inhibitory
effect of rituximab on dsg3-reactive but not TT-specific
CD4þ Th cells. TT has been frequently used as a model
antigen of memory CD4þ T cell responses (Cellerai et al.,
2007). Moreover, we did not find significant changes in
overall CD3þCD4þ T cell numbers, which is in line with
recent findings showing that rituximab did not alter major
T cells subsets in 21 pemphigus patients despite the pro-
nounced depletion of peripheral B cells (Musette et al., 2006;
Joly et al., 2007). A feasible explanation for the differential
TT-specific Th1 cells
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Figure 6. Tetanus toxoid (TT)-reactive CD4þ T cells and IgG antibodies are
not affected by rituximab. Panels (a) and (b) illustrate the numbers of IFNgþ
TT-reactive CD4þ T cells per 105 PBMC and titers of TT-specific IgG
antibodies of two investigated PV patients. In both patients, the frequencies of
TT-reactive Th1-cells remained unaffected by rituximab over the complete
12-month follow-up period. The titers of TT-specific IgG increased within the
12 month follow-up period after rituximab treatment.
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effect of rituximab on autoreactive versus pathogen-specific
CD4þ T cells may be that the latter do not need CD20þ B
cells as antigen-presenting cells. Thus, rituximab may exert a
differential effect on antigen-specific central versus effector
memory T cells. The selective effect of rituximab on anti-
dsg3-reactive autoab, but not TT-specific IgG, is also in line
with previous studies in rheumatoid arthritis, systemic lupus
erythematosus, and pemphigus, which showed that the IgG
titers against pathogens such as pneumococcal capsular
polysaccharides or TT did not change significantly upon
rituximab treatment (Cambridge et al., 2003; Arin et al.,
2005; Stohl and Looney, 2006; Vallerskog et al., 2006). The
effect of rituximab on the production of autoab suggests that
their secretion largely depends on the constant generation of
rather short-lived plasma cells from CD20þ memory B cells.
At present, rituximab has been mainly employed in a
strictly adjuvant setting in pemphigus (Arin et al., 2005). The
optimal combination with additional immunosuppressive
drugs or other immunomodulatory agents such as high-dose
intravenous immunoglobulins (Ahmed et al., 2006) or
immunoadsorption (Niedermeier et al., 2007) needs to be
defined by prospective clinical trials. In this study, rituximab
was also given in an adjuvant setting, that is, in combination
with systemic glucocorticoids and immunosuppressive
drugs. The observed decline of dsg3-reactive CD4þ Th cells
was directly linked to rituximab treatment, as systemic
glucocorticoids and immunosuppressive adjuvants such
as azathioprine and mycophenolate mofetil alone had no
significant effect on the overall frequencies of dsg3-specific
Th1 and Th2 cells as recently reported (Veldman et al., 2003).
The herein described dual effect of rituximab in pemphi-
gus may change our current understanding of how rituximab
acts in clinically responsive, but not strictly antibody-
mediated, autoimmune diseases such as rheumatoid arthritis,
lupus erythematosus, vasculitis, and dermatomyositis.
MATERIALS AND METHODS
Patients and inclusion criteria
A total of 11 PV patients (5 males, 6 females, mean age: 52.1±14.2
years) were included in this study (Table 1). Diagnosis of PV was
confirmed by (1) flaccid blisters and erosions of skin and/or mucous
membranes, (2) histopathology revealing suprabasal acantholytic
blisters, (3) direct and indirect immunofluorescence microscopy of
perilesional skin biopsies and monkey esophagus, respectively,
demonstrating epidermal intercellular IgG and complement C3
deposits, and (4) detection of serum autoab by dsg1/dsg3-ELISA. All
patients demonstrated severe PV, defined by at least 30% involve-
ment of the body surface and/or at least 25% involvement of the oral/
genital mucosa. Furthermore, all patients demonstrated disease
activity refractory to combined systemic immunosuppressives,
including high-dose glucocorticoids and at least one adjuvant
immunosuppressive agent for at least 3 months. Each patient gave
written consent before inclusion in the study, which was approved
by the Ethics Committee of the Medical Faculty of Philipps-
University, Marburg. The study was conducted according to the
Declaration of Helsinki Principles.
Clinical and serological scoring
Disease activity was quantified by the recently introduced ABSIS
(Pfutze et al., 2007). Briefly, cutaneous lesions were scored by
affected body surface area multiplied by a weighting factor reflecting
the quality of the erosions (exsudative, dry, or re-epithelialized). For
mucosal lesions, involvement of defined anatomical areas was
quantified. Sera of the PV patients were subjected to ELISA (Mesacup
Desmoglein-Test, MBL, Naka-ku, Nagoya, Japan) for detection of
anti-dsg3/anti-dsg1 IgG autoab, which were expressed as protein
index value (PIV) in Uml1. Dsg3-reactive IgG1 and IgG4 isotypes
were detected by a modified commercial ELISA, utilizing horse-
radish peroxidase-conjugated sheep anti-human IgG1 and IgG4
(The Binding Site, 1:20,000), respectively, as secondary Ab and were
expressed as optical density.
Table 1. Clinical characteristics and autoantibody profile of the studied patients with severe and/or recalcitrant PV
Follow-up period (after
Autoantibody profile2
(before rituximab)
Patient Sex Age rituximab treatment) Clinical manifestation1 Anti-dsg1 Anti-dsg3
PV1 M 54 412 months Erosions of the oral and nasal mucosa, head, face, and trunk 103 549
PV2 M 68 412 months Erosions of the oral mucosa Negative 484
PV3 F 70 412 months Extensive, recalcitrant erosions of the trunk and oral mucosa 163 2,368
PV4 F 24 412 months Initially blisters of the oral mucosa, later seborrhoic areas 357 145
PV5 M 48 412 months Extensive erosions of the arms, legs, and trunk 901 956
PV6 F 51 412 months Severe erosions of the oral mucosa Negative 72
PV7 M 50 412 months Extensive erosions of the oral mucosa and head 82 1,294
PV8 F 44 412 months Erosions of oral mucosa, trunk, and eyes Negative 2,318
PV9 M 37 412 months Extensive blistering and erosions, seborrhoic areas 173 80
PV10 F 69 412 months Extensive erosions of oral and genital mucosa Negative 2,521
PV11 F 58 3 months Erosions and blisters of trunk, oral, and genital mucosa Negative 636
dsg, desmoglein; F, female; M, male; PV, pemphigus vulgaris.
1Immunosuppressive treatment regimen (see Materials and Methods).
2Expressed as Uml1.
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Treatment
Before rituximab, all the PV patients were on a standard immuno-
suppressive therapy consisting of systemic prednisolone (initial dose:
0.5–1.0mgkg1 day1) and azathioprine (1.5–2.5mgkg1 day1,
provided thiopurine-methyltransferase activity was normal) or
mycophenolate mofetil (2–3 gday1). Rituximab (MabThera, Roche,
Grenzach-Wyhlen, Germany) was given as an adjuvant treatment
consisting of 4 weekly i.v. infusions of 375mg per m2 body
surface area on days 1, 8, 15, and 22. Prednisolone doses were
logarithmically reduced according to the clinical response. After
tapering of prednisolone, azathioprine or mycophenolate mofetil
treatment was continued for additional 6 months and then gradually
reduced upon long-term clinical remission.
Production and purification of human recombinant dsg3
Recombinant PVhis, consisting of the entire ectodomain of human
dsg3 linked to an E-tag and a 6 histidine-tag was used as a source
of dsg3 for the in vitro assays. In brief, PVhis baculovirus was
amplified in SF21 insect cells, and PVhis was produced as described
previously (Ishii et al., 1997). Dsg3 was purified from culture
supernatants of baculovirus-infected insect cells over nickel-nitrilo-
triacetic acid-linked agarose (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions.
Ex vivo analysis of dsg3-reactive T-cell subsets by MACS
cytokine secretion assay
CPDA (citrate–phosphate–dextrose–adenine)-containing blood sam-
ples (B65ml per time point) were obtained for MACS-cytokine
secretion assays and 9ml EDTA-containing blood samples were used
for lymphocyte subset analyses.
After isolation of PBMCs by density gradient centrifugation from
blood using Lymphoprep (Axis Shield PoC AS, Oslo, Norway),
6 107 PBMC were suspended at 107 cellsml1 in RPMI 1640, 10%
pooled human serum, 100Uml1 penicillin, 100mgml1 strepto-
mycin, and 2mM L-glutamine. After ex vivo stimulation with dsg3
(10 mg PVhisml1) for 16 hours at 371C, 5% CO2, PBMC specimens
from each patient were divided into two equal aliquots each
containing 3 107 PBMC and were subsequently analyzed using
MACS cytokine secretion assay (Miltenyi Biotec, Bergisch Gladbach,
Germany). Different T-cell subsets were isolated according to their
cytokine secretion (that is, IL-4 for Th2- and IFNg for Th1-subset)
following the manufacturer’s protocol (Manz et al., 1995; Veldman
et al., 2003). Magnetic bead-sorted T cells were finally counted with
a hemocytometer and frequencies of dsg3-reactive T cells were
calculated as T cells per 105 PBMC. For quantification of TT-specific
CD4þ T cells, 1 107 PBMCs were incubated for 16 hours at 371C,
5% CO2 with TT (2mgml
1, Sigma, Schnelldorf, Germany) and
IFNgþ Th1 cells were quantified by MACS as described above.
Statistics
Not normally distributed continuous variables are shown as median±
range. Statistical significances were calculated using the Wilcoxon
test. Level of significance a was defined as less than 0.05 (Po0.05).
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SUPPLEMENTARY MATERIAL
Figure S1. The decline in dsg3-reactive CD4þ T cells precedes the decrease
of dsg3-specific autoantibodies.
Figure S2. Relapsing PV patients demonstrate an increase of dsg3-reactive
Th1 and Th2 cell frequencies 12 months after rituximab.
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